195 related articles for article (PubMed ID: 11983544)
1. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients.
Malouf MA; Chhajed PN; Hopkins P; Plit M; Turner J; Glanville AR
J Heart Lung Transplant; 2002 May; 21(5):547-54. PubMed ID: 11983544
[TBL] [Abstract][Full Text] [Related]
2. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
[TBL] [Abstract][Full Text] [Related]
3. The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review.
AlDabbagh MA; Gitman MR; Kumar D; Humar A; Rotstein C; Husain S
Am J Transplant; 2017 Mar; 17(3):770-781. PubMed ID: 27545492
[TBL] [Abstract][Full Text] [Related]
4. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient.
Aris RM; Maia DM; Neuringer IP; Gott K; Kiley S; Gertis K; Handy J
Am J Respir Crit Care Med; 1996 Dec; 154(6 Pt 1):1712-7. PubMed ID: 8970360
[TBL] [Abstract][Full Text] [Related]
5. Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases.
Babel N; Gabdrakhmanova L; Hammer M; Rosenberger C; Oppert M; Volk HD; Reinke P
Transpl Infect Dis; 2005; 7(3-4):133-6. PubMed ID: 16390402
[TBL] [Abstract][Full Text] [Related]
6. The role of valacyclovir on Epstein-Barr virus viral loads in pediatric liver transplantation patients.
Ozçay F; Arslan H; Bilezikçi B; Sevmiş S; Moray G; Haberal M
Transplant Proc; 2009 Sep; 41(7):2878-80. PubMed ID: 19765462
[TBL] [Abstract][Full Text] [Related]
7. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
McDiarmid SV; Jordan S; Kim GS; Toyoda M; Goss JA; Vargas JH; Martín MG; Bahar R; Maxfield AL; Ament ME; Busuttil RW
Transplantation; 1998 Dec; 66(12):1604-11. PubMed ID: 9884246
[TBL] [Abstract][Full Text] [Related]
8. Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients.
Courtwright AM; Burkett P; Divo M; Keller S; Rosas IO; Trindade A; Mody GN; Singh SK; El-Chemaly S; Camp PC; Goldberg HJ; Mallidi HR
Ann Thorac Surg; 2018 Feb; 105(2):441-447. PubMed ID: 29223419
[TBL] [Abstract][Full Text] [Related]
9. Impact of antiviral prophylaxis in adults Epstein-Barr Virus-seronegative kidney recipients on early and late post-transplantation lymphoproliferative disorder onset: a retrospective cohort study.
Ville S; Imbert-Marcille BM; Coste-Burel M; Garandeau C; Meurette A; Cantarovitch D; Giral M; Hourmant M; Blancho G; Dantal J
Transpl Int; 2018 May; 31(5):484-494. PubMed ID: 29057508
[TBL] [Abstract][Full Text] [Related]
10. A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients.
Levine SM; Angel L; Anzueto A; Susanto I; Peters JI; Sako EY; Bryan CL
Chest; 1999 Nov; 116(5):1273-7. PubMed ID: 10559086
[TBL] [Abstract][Full Text] [Related]
11. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
[TBL] [Abstract][Full Text] [Related]
12. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy.
Darenkov IA; Marcarelli MA; Basadonna GP; Friedman AL; Lorber KM; Howe JG; Crouch J; Bia MJ; Kliger AS; Lorber MI
Transplantation; 1997 Sep; 64(6):848-52. PubMed ID: 9326409
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder.
Humar A; Hébert D; Davies HD; Humar A; Stephens D; O'Doherty B; Allen U
Transplantation; 2006 Mar; 81(6):856-61. PubMed ID: 16570008
[TBL] [Abstract][Full Text] [Related]
14. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
Colombini E; Guzzo I; Morolli F; Longo G; Russo C; Lombardi A; Merli P; Barzon L; Murer L; Piga S; Ciofi Degli Atti ML; Locatelli F; Dello Strologo L
Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
[TBL] [Abstract][Full Text] [Related]
15. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
Mentzer SJ; Perrine SP; Faller DV
Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
[TBL] [Abstract][Full Text] [Related]
16. Case Report: Non-negligible Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in a lung transplant recipient.
Hu J; Yu YW; Han DS; Li XJ; Zhang YQ; Cai HL; Xiao YH; Zheng X
Front Immunol; 2023; 14():1244534. PubMed ID: 37781359
[TBL] [Abstract][Full Text] [Related]
17. Post-transplant lymphoproliferative disease in lung transplantation: A nested case-control study.
Leyssens A; Dierickx D; Verbeken EK; Tousseyn T; Verleden SE; Vanaudenaerde BM; Dupont LJ; Yserbyt J; Verleden GM; Van Raemdonck DE; Vos R
Clin Transplant; 2017 Jul; 31(7):. PubMed ID: 28383790
[TBL] [Abstract][Full Text] [Related]
18. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients.
Riddler SA; Breinig MC; McKnight JL
Blood; 1994 Aug; 84(3):972-84. PubMed ID: 8043879
[TBL] [Abstract][Full Text] [Related]
19. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children.
Green M; Bueno J; Rowe D; Mazariegos G; Qu L; Abu-Almagd K; Reyes J
Transplantation; 2000 Aug; 70(4):593-6. PubMed ID: 10972215
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: a case-control study.
Allen UD; Farkas G; Hébert D; Weitzman S; Stephens D; Petric M; Tellier R; Ngan B; Fecteau A; West L; Wasfy S
Pediatr Transplant; 2005 Aug; 9(4):450-5. PubMed ID: 16048596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
